10-Q: P3 Health Partners Q3 2025: Losses Persist, Liquidity Concerns

P3 Health Partners Inc. reports continued net losses and a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern, despite strategic contract terminations and new debt financing.

Summary

• Net loss for the three months ended September 30, 2025, was $69.5 million, an improvement from $102.9 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $157.4 million, compared to $181.2 million for the same period in 2024.
• Total operating revenue decreased by 5% to $345.3 million for Q3 2025 and 5% to $1.07 billion for the nine months ended September 30, 2025, primarily driven by a 10% decrease in average at-risk members.
• Medical expense decreased by 8% to $369.8 million for Q3 2025 and 5% to $1.09 billion for the nine months ended September 30, 2025, attributed to fewer at-risk members and the termination of two health plans.
• A premium deficiency reserve benefit of $23.7 million was recorded for Q3 2025, a significant improvement from an $18.2 million expense in Q3 2024, reflecting management's assessment of improved contract profitability.
• Corporate, general and administrative expenses decreased by 19% to $22.1 million for Q3 2025 and 13% to $70.4 million for the nine months ended September 30, 2025, due to headcount reduction and the sale of Florida operations.
• The company had $37.7 million in unrestricted cash as of September 30, 2025, a slight decrease from $38.8 million at December 31, 2024.
• A working capital deficit of $288.3 million was reported as of September 30, 2025.
• The company completed a 1-for-50 reverse stock split on April 11, 2025, to regain compliance with Nasdaq's minimum bid price rule.
• New debt financing included the VGS 4 Promissory Note for up to $30.0 million and the VGS 5 Promissory Note for up to $70.0 million, both carrying a high interest rate of 19.5% per annum, predominantly paid in-kind.
• Substantial doubt exists about the company's ability to continue as a going concern within one year after the financial statements' issuance date.
• The Term Loan Agreement was amended on August 27, 2025, extending the interest-only period and final maturity date, and was accounted for as a troubled debt restructuring.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by persistent net losses, a substantial working capital deficit, explicit going concern doubt, and reliance on high-interest debt. While some cost-cutting and strategic contract terminations are noted, the overall financial health is very poor, and future viability is uncertain without significant capital infusion.

Positives

• Net loss decreased to $69.5 million for Q3 2025 from $102.9 million in Q3 2024, and to $157.4 million for the nine months ended September 30, 2025, from $181.2 million in the prior year period.
• Premium deficiency reserve showed a benefit of $23.7 million in Q3 2025, a significant improvement from an $18.2 million expense in Q3 2024, indicating management's expectation of reduced future losses from contracts.
• Corporate, general and administrative expenses decreased by 19% in Q3 2025 and 13% year-to-date, driven by headcount reduction and the sale of Florida operations, reflecting cost-cutting efforts.
• The company regained compliance with Nasdaq's minimum bid price rule after a 1-for-50 reverse stock split.
• New debt financing (VGS 4 and VGS 5 Promissory Notes) secured up to $100 million in total, providing additional liquidity.
• Formation of P3 Commonwealth Innovation MSO, LLC in November 2025, a strategic move to improve performance and quality of ACO programs.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern within one year due to accumulated losses and a significant working capital deficit.
• Net losses persist, with $69.5 million in Q3 2025 and $157.4 million for the nine months ended September 30, 2025.
• Total operating revenue decreased by 5% for both the three and nine months ended September 30, 2025, primarily due to a 10% decrease in at-risk members.
• The company reported a significant working capital deficit of $288.3 million as of September 30, 2025.
• Unrestricted cash decreased to $37.7 million as of September 30, 2025, from $38.8 million at December 31, 2024.
• Interest expense, net, significantly increased to $20.5 million in Q3 2025 from $5.6 million in Q3 2024, and to $39.4 million for the nine months ended September 30, 2025, from $15.3 million in the prior year, reflecting higher debt levels and rates.
• The new VGS promissory notes carry very high interest rates (19.5% per annum), predominantly paid in-kind, which will further increase debt principal.
• The Term Loan Agreement was amended as a troubled debt restructuring, explicitly indicating financial difficulties.
• The company is subject to a Civil Investigative Demand from the DOJ regarding arrangements with insurance agents and brokers.
• At-risk membership decreased by 10% for Q3 2025 and 9% year-to-date, driven by strategic termination of underperforming contracts and affiliate providers.

Risks

• Ability to continue as a going concern.
• Need to raise additional capital to fund existing operations, develop new services, or expand operations.
• History of net losses and expectation to continue incurring losses for the foreseeable future, with no assurance of achieving or maintaining profitability.
• Inability to maintain compliance with debt covenants, potentially leading to an event of default.
• Relatively limited operating history making future prospects and challenges difficult to evaluate.
• Significant portion of assets consists of other intangible assets, whose value may be reduced if impaired.
• Reliance on management team and key employees; inability to retain qualified personnel could harm business.
• Growth depends on identifying and developing successful new geographies, physician partners, payors, and patients; failure to execute growth strategies could have a material adverse effect.
• Decrease in growth of patients and physician partners, or services provided, due to legal, economic, or business developments could harm business.
• Primary dependence on capitation payments from third-party payors and individuals, leading to potential delays, uncertainties, and disagreements regarding payments, including changes or reductions in Medicare reimbursement rates.
• Termination or non-renewal of Medicare Advantage (MA) contracts with health plans, or contracts with those plans, could materially adversely affect revenue and operations.
• Dependence on affiliated professional entities and other physician partners/providers to effectively manage quality and cost of care and perform obligations under payor contracts.
• Reductions in quality ratings of health plans served could materially adversely affect business.
• Developments affecting spending by the healthcare industry could adversely affect business.
• Information technology system failures, security breaches, cyberattacks, or other cybersecurity deficiencies could harm business.
• Actual or perceived failures to comply with applicable data protection, privacy and security laws could adversely affect business.
• Operating in a heavily regulated industry; failure to adhere to complex government laws and regulations could result in fines, penalties, operational changes, or adverse publicity.
• Arrangements with affiliated professional entities and other physician partners found to constitute improper rendering of medical services or fee splitting under state laws could adversely impact business.
• Inspections, reviews, audits, and investigations under federal and state government programs and contracts could have adverse findings.
• Impact of recent healthcare legislation and other changes in the healthcare industry and spending is unknown but may adversely affect business.
• Only significant asset is minority ownership of economic interest in P3 LLC, which may not be sufficient to meet financial obligations or pay dividends.
• Required to make significant payments under the Tax Receivable Agreement for certain tax benefits.
• Foresight Sponsor Group, LLC and affiliates are not limited in their ability to compete, and corporate opportunity provisions could enable them to benefit from opportunities otherwise available to the company, presenting conflicts of interest.
• Failure to satisfy California regulations related to financial solvency and operational performance could result in sanctions for affiliated physician groups and Restricted Knox-Keene licensed health plans.
• Failure to meet Nasdaq Capital Market continued listing requirements could result in delisting of securities.
• Failure to maintain effective internal control over financial reporting could have a material adverse effect on business and stock price.
• The Civil Investigative Demand from the DOJ concerning arrangements with insurance agents and brokers could lead to fines or penalties.

Future Outlook

The company expects to continue incurring net losses, comprehensive losses, and negative cash flows from operating activities. It aims to generate operating efficiencies and expects platform support costs to decrease as a percentage of revenue over time. The company also anticipates PMPM revenue to improve as members participate longer in its care model due to better health status assessment and documentation. However, there is substantial doubt about its ability to continue as a going concern, and it is actively exploring additional debt and/or equity financing, with no assurance such financing will be available on acceptable terms.

Management Comments

• We believe that the misaligned incentives in the fee-for-service (FFS) healthcare payment model and the fragmentation between physicians and care teams has led to sub-optimal clinical outcomes, limited access, high spending and unnecessary variability in the quality of care.
• We believe that a platform such as ours, which helps to realign incentives and focuses on treating the full patient, is uniquely positioned to address these healthcare challenges.
• Our contracted recurring revenue model offers us highly predictable revenue and rewards us for providing high-quality care rather than driving a high volume of services.
• In this capitated arrangement, our goals are well-aligned with payors and patients alikethe more we improve health outcomes, the more profitable we will be over time.
• Keeping members healthy is our primary objective. When they need medical care, delivery of the right care in the right setting can greatly impact outcomes.
• We expect that our PMPM revenue will continue to improve the longer members participate in our care model as we better understand and assess their health status (acuity) and coordinate their medical care.
• We aim to generate operating efficiencies at both the market and enterprise level.
• We expect our corporate, general and administrative expenses to increase in absolute dollars in the future as we continue to invest to support growth of our business, as well as due to the costs required to operate as a public company.
• As of the date of this Form 10-Q, we believe that our existing cash resources are not sufficient to support planned operations for at least the next year from the issuance of the unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q.
• As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q are issued.

Industry Context

P3 Health Partners operates in the Medicare Advantage (MA) market, a significant segment of the broader Medicare market, which covered over 69 million eligible lives as of April 2025. The company's model focuses on value-based care (VBC) and population health management, aiming to address misaligned incentives and fragmentation in the traditional fee-for-service healthcare system. The strategic termination of underperforming contracts and the formation of the P3 Commonwealth Innovation MSO, LLC suggest a focus on optimizing existing operations and expanding into new collaborative models within the VBC space, aligning with broader industry trends towards quality-based outcomes and cost management. However, the company's financial struggles highlight the challenges of achieving profitability in this complex and heavily regulated sector, especially with adverse claims experience partly driven by general market conditions for MA plans.

Comparison to Industry Standards

• The company's reported net losses and working capital deficit are significantly below industry standards for healthy, growing healthcare providers.
• The high interest rates (19.5% PIK) on new promissory notes (VGS 4 and VGS 5) indicate a distressed financial situation, as such rates are typically associated with high-risk lending, far exceeding standard corporate borrowing costs.
• The classification of the Tenth Amendment to the Term Loan Agreement as a "troubled debt restructuring" explicitly signals severe financial difficulties, a condition that is a red flag compared to financially stable industry peers.
• The decrease in at-risk membership and affiliate primary care physicians, while attributed to strategic terminations, contrasts with the growth objectives often seen in successful value-based care models.
• The ongoing Civil Investigative Demand from the DOJ regarding broker arrangements suggests potential regulatory compliance issues, which could impact reputation and operations, unlike companies with clean regulatory records.

Corporate Governance

Legal Proceedings

• The company received a Civil Investigative Demand (CID) from the United States Department of Justice (DOJ) in June 2024, pursuant to the False Claims Act.
• The investigation concerns the company's arrangements with insurance agents and brokers, requesting documentation and information related to marketing broker programs, arrangements with, and remuneration paid to MA brokers, agents, and agencies, and arrangements with third parties.
• The company is cooperating with the investigation.
• No assurance can be given as to the timing or outcome of the government's investigation.

Related Party Transactions

• P3 LLC entered into a VGS 4 Promissory Note with VBC Growth SPV 4, LLC (VGS 4), a related party, for up to $30.0 million.
• P3 LLC entered into a VGS 5 Promissory Note with VBC Growth SPV 5, LLC (VGS 5), a related party, for up to $70.0 million.
• Chicago Pacific Founders (CPF), a principal equity holder, has an equity investment in Allymar Health Solutions and Nevada Behavioral Health Systems.
• The company has a master services agreement with Allymar for support services, incurring $3.8 million in expenses for Q3 2025 and $5.1 million for the nine months ended September 30, 2025.
• The company has a managed behavioral health agreement with Nevada Behavioral Health Systems, incurring an immaterial amount of service expense for Q3 and YTD 2025.
• The VGS 4 and VGS 5 Promissory Notes include up-front fees (1.5% in-kind) and back-end fees (up to 9.0%) payable to the related parties.

Stakeholder Impact

• Shareholders: Significant dilution risk from potential future equity issuances. Continued net losses and going concern doubt pose a severe risk to investment value. The reverse stock split temporarily addressed Nasdaq listing but doesn't guarantee sustained stock price or liquidity.
• Creditors: The Term Loan Agreement was amended as a troubled debt restructuring, indicating increased risk. New promissory notes from related parties are subordinated, further complicating recovery for other lenders in a default scenario. High interest rates on new debt increase the company's financial burden.
• Employees: Reduction in headcount due to cost-cutting measures and sale of Florida operations indicates job insecurity.
• Customers (Health Plans/Members): Strategic termination of underperforming payor contracts and affiliate providers could lead to changes in service providers or network access for some members. The focus on improving care quality and cost management through the P3 Care Model aims to benefit members in the long term, but financial instability could disrupt services.
• Suppliers/Physician Partners: Strategic termination of underperforming affiliate providers impacts those physicians. Financial instability could affect timely payments or contract renewals.

Next Steps

• Continue exploring raising additional capital through debt financing and equity issuances.
• Manage medical costs and the maturity of its members.
• Potentially curtail planned activities, discontinue certain operations, or sell certain assets if unable to raise additional capital.
• Cooperate with the Civil Investigative Demand from the United States Department of Justice.
• P3 Commonwealth Innovation MSO, LLC will begin receiving a portion of each ACO's net shared savings starting in 2026.
• P3 ACO has the right to cause the MSO to redeem CPC ACO's membership interests after the three-year anniversary of the MSO's formation.
• CPC ACO has the right to cause the MSO to redeem its membership interests if P3 ACO does not exercise its redemption right within 90 days following the date such right is exercisable.

Key Dates

Recommendation

The filing reveals a company in severe financial distress, explicitly stating "substantial doubt about its ability to continue as a going concern." Despite a reduction in net losses, revenue is declining due to a decrease in at-risk members, and the company carries a significant working capital deficit of $288.3 million. New debt financing comes with extremely high 19.5% PIK interest rates, and the Term Loan Agreement was restructured as a "troubled debt restructuring," all clear indicators of a precarious financial position. While cost-cutting and strategic exits from underperforming contracts are underway, these measures are insufficient to offset the fundamental issues. The ongoing DOJ investigation adds further regulatory risk. Given the high probability of further dilution, potential inability to secure future financing on favorable terms, and the explicit going concern warning, the stock presents an exceptionally high risk with limited upside potential in the near to medium term.

Keywords

P3 Health Partners, PIII, 10-Q, Quarterly Report, Medicare Advantage, Population Health Management, Healthcare, Financial Results, Net Loss, Revenue, Capitation, Medical Expense, Going Concern, Liquidity, Debt Financing, Promissory Note, Reverse Stock Split, Nasdaq Listing, Risk Factors, SEC Filing, Value-Based Care, VBC, Health Plans, Physician Network, Working Capital Deficit, Troubled Debt Restructuring, Civil Investigative Demand, California Regulations, Corporate Governance